October 13, 2022
RegMed Investors’ (RMi) pre-open: pivot means change away or towards risks which are high while rewards are low
October 12, 2022
RegMed Investors’ (RMi) pre-open: producer price report weighs the session
October 11, 2022
RegMed Investors’ (RMi) pre-open: is a short-term bottom close – not by a long-shot?
October 10, 2022
RegMed Investors’ (RMi) pre-open: the share pricing game, musical chairs
October 7, 2022
RegMed Investors’ (RMi) pre-open: resistance and key jobs report posts the number, 263,000 with unemployment 3.5%
October 6, 2022
RegMed Investors’ (RMi) pre-open: tick, tock; where’s the price of cell and gene therapy stocks going
October 5, 2022
RegMed Investors’ (RMi) pre-open: silly question yet, will the cell and gene therapy sector outperform its daily spin?
October 4, 2022
RegMed Investors’ (RMi) pre-open: buy a few dips and a mixed bag of indications
October 3, 2022
RegMed Investors’ (RMi) pre-open: Q4 kicks off
September 30, 2022
RegMed Investors’ (RMi) pre-open: liquidity, an issue as month and Q3 close
September 29, 2022
RegMed Investors’ (RMi) pre-open: what now, after I wrote “sell into any strength”?
September 28, 2022
RegMed Investors’ (RMi) pre-open: sell into any strength as U.S. and global markets fall
September 27, 2022
RegMed Investors’ (RMi) pre-open: when you have to take a stock’s value beat-down, just think recovery
September 26, 2022
RegMed Investors’ (RMi) pre-open: what goes down for five (5) sector moves last week, needs some back-fill
September 23, 2022
RegMed Investors’ (RMi) pre-open: recession dents your appetite, whether investors want to admit it
September 22, 2022
RegMed Investors’ (RMi) pre-open: is there a “Terminal Rate” for cell and gene therapy sector equities
September 21, 2022
RegMed Investors’ (RMi) pre-open: Fed policy decision day at 2:30p.m.
September 20, 2022
RegMed Investors’ (RMi) pre-open: the limbo dance, how low can the cell and gene therapy sector go and inflation “readings”?
September 19, 2022
News RegMed Investors’ (RMi) pre-open: Investors are getting spooked, reality is a _itch
September 16, 2022
RegMed Investors’ (RMi) pre-open: Humpty-Dumpty had a great fall
September 15, 2022
RegMed Investors’ (RMi) pre-open: will sector’s share pricing be risk/reward exposed?
September 14, 2022
RegMed Investors’ (RMi) pre-open: after a fall on Tuesday’, there’s still blood on the street as Producer Price Index (PPI) is down -0.1%
September 13, 2022
RegMed Investors’ (RMi) pre-open: watch and wait to make a buck
September 12, 2022
RegMed Investors’ (RMi) pre-open: to SELL or to BUY? Is a big dive coming; does low volume forecast the moves?
September 9, 2022
RegMed Investors’ (RMi) pre-open: share pricing runs
2 hours 15 min ago
RMi Closing Bell: Snow shoeing through Ai and cell and gene therapy sector blizzard
11 hours 22 min ago
RMi Pre-opening: Shovel-out the portfolio
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.